Program
QRX003
A development code. Also written as “QRX003, 4% Lotion”, “QRX003-2% Lotion” and “QRX003-4% Lotion QAM”.
Its studies are mostly in Netherton Syndrome, led by Quoin Pharmaceuticals.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Quoin Pharmaceuticals | 44 open or running | phase 3since Aug 17, 2022 | Aug 17, 2022 | Dec 30, 2026phase 3 · NCT05789056 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 17, 2022First study: phase 3 study in Netherton SyndromeFirst studyNCT05521438 · 30 enrolled · United States
- Mar 16, 2023Phase 3 study in Netherton SyndromeNCT05789056 · 20 planned · United States
- Apr 7, 2025Phase 3 study in Netherton SyndromeNCT06953466 · 8 planned · United States
- Mar 24, 2026Phase 3 study in Netherton SyndromeNCT07538583 · 16 planned · United States, United Kingdom
Ahead
- Dec 30, 2026Primary completion: phase 3 study in Netherton SyndromeNCT06953466
- Dec 30, 2026Primary completion: phase 3 study in Netherton SyndromeNCT05789056
- Jan 31, 2027Primary completion: phase 3 study in Netherton SyndromeNCT07538583
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07538583Netherton Syndrome · United States, United Kingdom | 3 | Recruiting | Jan 31, 2027 | 16 |
| NCT06953466Netherton Syndrome · United States | 3 | Recruiting | Dec 30, 2026 | 8 |
| NCT05789056Netherton Syndrome · United States | 3 | Recruiting | Dec 30, 2026 | 20 |
| NCT05521438Netherton Syndrome · United States | 3 | Active, not recruiting | Dec 30, 2025 | 30 |
How it is read
Names in the registry
- “QRX003, 4% Lotion”, 2 entries
- “QRX003”, 1 entry
- “QRX003-2% Lotion”, 1 entry
- “QRX003-4% Lotion QAM”, 1 entry
- “QRX003-4% Lotion BID”, 1 entry
Codes read as this program: QRX003.
Conditions, from the studies’ own filings
- Netherton Syndrome, 4 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.